论文部分内容阅读
目的探讨氯硝西泮在Wada试验中的临床应用价值。方法回顾分析我科自2006年7月至2010年6月,准备外科治疗的106例难治性颞叶癫痫患者,用氯硝西泮替代异戊巴比妥行Wada试验。结果 106例病人均未出现明显不良反应,测试后30分钟到60分钟均基本恢复到测试前意识水平。101例通过测试者行前颞叶切除术,其中3例术后出现短暂语言迟钝,经观察脱水治疗3～7天后逐渐恢复,其余病人术后均未出现明显的语言障碍及记忆功能缺失。结论氯硝西泮在有效性、安全性上均达到临床用药要求,可以替代异戊巴比妥应用于Wada试验。
Objective To investigate the clinical value of clonazepam in Wada test. Methods A retrospective analysis of our department from July 2006 to June 2010, prepared for surgical treatment of 106 patients with intractable temporal lobe epilepsy, with clonazepam instead of amylobarbital Wada test. Results There were no obvious adverse reactions in 106 patients. After 30 minutes to 60 minutes, all the patients returned to the pre-test level of consciousness. One hundred and one patients who passed the test underwent anterior temporal lobe resection. Three of them had transient postoperative shortness of breath and gradually recovered after 3 to 7 days of dehydration. No obvious language impairment and memory loss occurred in the rest of the patients. Conclusion Clonazepam can meet the clinical requirements of efficacy and safety and can be used in place of pentobarbital in Wada test.